Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of lncRNA SNHG7 in preparation of medicine for treating retinopathy

A technology for retinopathy and retina, applied in the field of application in the preparation of drugs for the treatment of retinopathy

Inactive Publication Date: 2021-09-03
THE FIRST PEOPLES HOSPITAL OF NANTONG
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Whether SNHG7 is involved in the regulation of EndMT, whether it is transferred by MSC-exo, there is no relevant literature to report

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lncRNA SNHG7 in preparation of medicine for treating retinopathy
  • Application of lncRNA SNHG7 in preparation of medicine for treating retinopathy
  • Application of lncRNA SNHG7 in preparation of medicine for treating retinopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] 1. Materials and methods

[0037] 1.1 Cell culture and treatment

[0038] Human retinal microvascular endothelial cells (HRMECs) were obtained from the American Type Culture Collection (USA) and grown in the presence of 10% fetal bovine serum (FBS; Invitrogen, USA), 1% penicillin / streptomycin (Invitrogen), endothelial cells Factor (EGM; SingleQuots, Clonetics, San Diego, USA) in endothelial basal medium (LonzaGroup, Switzerland); cells were incubated in 5% CO 2 Maintain the culture at 37 °C under humidified conditions. For high glucose treatment, HRMECs treated with 30 mM dextrose ((Sigma, USA) for 48 h, treated with normal glucose (5.5 mM) or mannitol (24.5 mM) plus glucose (5.5 mM) were used as controls. For cells For transfection, OE-NC (negative control plasmid), OE-SNHG7, miR-NC, miR-34a-5p mimic, inhibitor NC, miR-34a were transfected with Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) -5p inhibitor, sh-NC, sh-XBP1 delivered in the cell.24 hours after the t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biology, and particularly relates to application of lncRNA SNHG7 in preparation of a medicine for treating retinopathy. The lncRNA SNHG7 is derived from an exosome of a bone marrow mesenchymal stem cell. Through the interaction with the miR-34a-5p / XBP1 signal pathway, the exosome SNHG7 derived from the mesenchymal stem cells can inhibit the EndMT and tube formation of HRMECs induced by high glucose exposure, which may provide a feasible therapeutic target for the treatment of diabetic retinopathy.

Description

technical field [0001] The invention belongs to the field of biology, and in particular relates to an application of lncRNA SNHG7 in the preparation of drugs for treating retinopathy. Background technique [0002] Diabetic retinopathy (DR) is one of the most serious neurovascular complications of type 2 diabetes mellitus (T2DM) and the leading cause of vision-impairing blindness. Retinal endothelial cells serve as the first barrier to monitor changes in blood glucose, and evidence has shown that high glucose (HG) initiates retinal endothelial cell proliferation and migration, which are key steps in the development of DR. Although a new generation of drugs and vitreoretinal microsurgery have been applied clinically to treat DR, the prevalence of DR has risen sharply in the past decades. Therefore, further elucidation of the etiology of DR is crucial to improving currently available treatments. [0003] Endothelial to mesenchymal transition (EndMT), characterized by decrea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7088A61P3/10A61P9/10A61P27/02C12N5/10
CPCA61K31/7088A61P3/10A61P9/10A61P27/02C12N5/0621C12N15/113C12N2310/141
Inventor 曹鑫宋愈俞小莉蔡剑茹谢擎薛理丹黄黎黎蔡骐
Owner THE FIRST PEOPLES HOSPITAL OF NANTONG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com